Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Reid W. Merryman*, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A. Bond, Samantha Jaglowski, Michael A. Spinner, Sally Arai, Robert Lowsky, Gunjan L. Shah, Miguel Angel Perales, Jean Marc Schiano De Colella, Didier Blaise, Alex F. Herrera, Geoffrey Shouse, Chloe Spilleboudt, Stephen M. AnsellYago Nieto, Talha Badar, Mehdi Hamadani, Tatyana A. Feldman, Lori Dahncke, Anurag K. Singh, Joseph P. McGuirk, Taiga Nishihori, Julio Chavez, Anthony V. Serritella, Justin Kline, Mohamad Mohty, Remy Dulery, Aspasia Stamatoulas, Roch Houot, Guillaume Manson, Marie Pierre Moles-Moreau, Corentin Orvain, Kamal Bouabdallah, Dipenkumar Modi, Radhakrishnan Ramchandren, Lazaros Lekakis, Amer Beitinjaneh, Matthew J. Frigault, Yi Bin Chen, Ryan C. Lynch, Stephen D. Smith, Uttam Rao, Michael Byrne, Jason T. Romancik, Jonathon B. Cohen, Sunita Nathan, Tycel Phillips, Robin M. Joyce, Maryam Rahimian, Asad Bashey, Hatcher J. Ballard, Jakub Svoboda, Valter Torri, Martina Sollini, Chiara De Philippis, Massimo Magagnoli, Armando Santoro, Philippe Armand, Pier Luigi Zinzani, Carmelo Carlo-Stella

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. With a median follow-up among survivors of 24 months, the 2-year cumulative incidences (CIs) of non-relapse mortality and relapse were 14 and 18%, respectively; the 2-year graft-versus-host disease (GVHD) and relapse-free survival (GRFS), progression-free survival (PFS), and overall survival were 47%, 69%, and 82%, respectively. The 180-day CI of grade 3–4 acute GVHD was 15%, while the 2-year CI of chronic GVHD was 34%. In multivariable analyses, a longer interval from PD-1 to alloHCT was associated with less frequent severe acute GVHD, while additional treatment between PD-1 and alloHCT was associated with a higher risk of relapse. Notably, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis was associated with significant improvements in PFS and GRFS. While awaiting prospective clinical trials, PTCy-based GVHD prophylaxis may be considered the optimal transplantation strategy for this patient population.

Original languageEnglish (US)
Pages (from-to)2672-2683
Number of pages12
JournalLeukemia
Volume35
Issue number9
DOIs
StatePublished - Sep 2021
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this